COMMUNITY
Rheonix® has established worldwide corporate, governmental, and educational partnerships. To discuss a partnership that brings our platform technology to your existing or future products or services, please contact us.
Rheonix is engaged in multiple corporate-funded partnerships addressing a variety of applications that can benefit from the Rheonix CARD® (Chemistry And Reagent Device) system:
- In vitro diagnostics, including immunoassay, molecular assays, and receptor-based assays
- Protein/Nucleic Acid purification
- Environmental testing, including food and water testing
- Bioburden testing during the manufacture of products in the biopharm, food and beverage, and personal care markets
- Flow injection analysis
A number of important collaborations with major universities have allowed Rheonix to gain third-party validation of the utility of the Rheonix CARD system:
- New York University (New York, NY, USA)
- University of Pennsylvania (Philadelphia, PA, USA)
- Leiden University (Leiden, The Netherlands)
- Cornell University (Ithaca, NY, USA)
Rheonix is currently the recipient of government funds to explore the development of systems that meet specific detection needs for infectious disease and pathogen identification:
- National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID)
- United States Environmental Protection Agency (US EPA)
- National Science Foundation (NSF)
A joint venture with Beijing Bohui Innovative Technology Co., Ltd. (Beijing, China) provides Rheonix with not only access to the expanding diagnostic markets in China, but also state-of-the-art medical device manufacturing facilities. Rheonix anticipates the launch of a commercialized HPV Rheonix CARD system through this joint venture in the second half of 2010.
To discuss a partnership utilizing the Rheonix CARD system,
please contact us.
